Use of coptidis Rhizoma and foetal growth: A follow-up study of 9895 pregnancies

Chao Hua Chuang, Jung Nien Lai, Jung-Der Wang, Pei Jen Chang, Pau Chung Chen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: To explore the effect or Coptidis Rhizoma on foetal growth in pregnancy. Methods: During 1985-1987, each pregnant woman with 26 or more weeks of gestation who came to the Taipei Municipal Maternal and Child Hospital for prenatal care was enrolled and interviewed by three trained interviewers using structured questionnaires to obtain detailed information including the herbal medicines used during pregnancy. Medical histories of diabetes, hypertension, antepartum haemorrhage and medicines used during pregnancy were abstracted from medical records of mothers'. Data of birth weight, gestational duration and characteristics of infants were gathered from the Taiwan national birth registration. A total of 9895 singleton livebirths were analysed. The variables related to foetal growth included two dichotomous measures: low birth weight (LBW) and small for gestational age (SGA); and one continuous measure: birth weight. Potential risk factors associated with these outcomes were investigated using multiple logistic and linear regression models. Results: After adjustment, pregnant women taking Coptidis Rhizoma during pregnancy had no significantly adverse effect on foetal growth. There was a non-significantly slightly decreased mean of birth weight and increased risk of LBW and SGA babies if the frequency of using Coptidis Rhizoma was more than 56 times. Conclusions: The usual usage of Coptidis Rhizoma during pregnancy seemed not to increase the adverse risk on foetal growth. Future observations for use of longer than 56 times or a higher cumulated dose were needed to clarify the safety.

Original languageEnglish
Pages (from-to)185-192
Number of pages8
JournalPharmacoepidemiology and drug safety
Volume15
Issue number3
DOIs
Publication statusPublished - 2006 Mar 1

Fingerprint

Fetal Development
Pregnancy
Birth Weight
Low Birth Weight Infant
Gestational Age
Pregnant Women
Linear Models
Mothers
Social Adjustment
Prenatal Care
Herbal Medicine
Taiwan
Medical Records
Logistic Models
Parturition
Interviews
Hemorrhage
Hypertension
Safety

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Pharmacology (medical)

Cite this

Chuang, Chao Hua ; Lai, Jung Nien ; Wang, Jung-Der ; Chang, Pei Jen ; Chen, Pau Chung. / Use of coptidis Rhizoma and foetal growth : A follow-up study of 9895 pregnancies. In: Pharmacoepidemiology and drug safety. 2006 ; Vol. 15, No. 3. pp. 185-192.
@article{f4f3e81ffe544c9a9a42b88810ecda63,
title = "Use of coptidis Rhizoma and foetal growth: A follow-up study of 9895 pregnancies",
abstract = "Purpose: To explore the effect or Coptidis Rhizoma on foetal growth in pregnancy. Methods: During 1985-1987, each pregnant woman with 26 or more weeks of gestation who came to the Taipei Municipal Maternal and Child Hospital for prenatal care was enrolled and interviewed by three trained interviewers using structured questionnaires to obtain detailed information including the herbal medicines used during pregnancy. Medical histories of diabetes, hypertension, antepartum haemorrhage and medicines used during pregnancy were abstracted from medical records of mothers'. Data of birth weight, gestational duration and characteristics of infants were gathered from the Taiwan national birth registration. A total of 9895 singleton livebirths were analysed. The variables related to foetal growth included two dichotomous measures: low birth weight (LBW) and small for gestational age (SGA); and one continuous measure: birth weight. Potential risk factors associated with these outcomes were investigated using multiple logistic and linear regression models. Results: After adjustment, pregnant women taking Coptidis Rhizoma during pregnancy had no significantly adverse effect on foetal growth. There was a non-significantly slightly decreased mean of birth weight and increased risk of LBW and SGA babies if the frequency of using Coptidis Rhizoma was more than 56 times. Conclusions: The usual usage of Coptidis Rhizoma during pregnancy seemed not to increase the adverse risk on foetal growth. Future observations for use of longer than 56 times or a higher cumulated dose were needed to clarify the safety.",
author = "Chuang, {Chao Hua} and Lai, {Jung Nien} and Jung-Der Wang and Chang, {Pei Jen} and Chen, {Pau Chung}",
year = "2006",
month = "3",
day = "1",
doi = "10.1002/pds.1170",
language = "English",
volume = "15",
pages = "185--192",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

Use of coptidis Rhizoma and foetal growth : A follow-up study of 9895 pregnancies. / Chuang, Chao Hua; Lai, Jung Nien; Wang, Jung-Der; Chang, Pei Jen; Chen, Pau Chung.

In: Pharmacoepidemiology and drug safety, Vol. 15, No. 3, 01.03.2006, p. 185-192.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of coptidis Rhizoma and foetal growth

T2 - A follow-up study of 9895 pregnancies

AU - Chuang, Chao Hua

AU - Lai, Jung Nien

AU - Wang, Jung-Der

AU - Chang, Pei Jen

AU - Chen, Pau Chung

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Purpose: To explore the effect or Coptidis Rhizoma on foetal growth in pregnancy. Methods: During 1985-1987, each pregnant woman with 26 or more weeks of gestation who came to the Taipei Municipal Maternal and Child Hospital for prenatal care was enrolled and interviewed by three trained interviewers using structured questionnaires to obtain detailed information including the herbal medicines used during pregnancy. Medical histories of diabetes, hypertension, antepartum haemorrhage and medicines used during pregnancy were abstracted from medical records of mothers'. Data of birth weight, gestational duration and characteristics of infants were gathered from the Taiwan national birth registration. A total of 9895 singleton livebirths were analysed. The variables related to foetal growth included two dichotomous measures: low birth weight (LBW) and small for gestational age (SGA); and one continuous measure: birth weight. Potential risk factors associated with these outcomes were investigated using multiple logistic and linear regression models. Results: After adjustment, pregnant women taking Coptidis Rhizoma during pregnancy had no significantly adverse effect on foetal growth. There was a non-significantly slightly decreased mean of birth weight and increased risk of LBW and SGA babies if the frequency of using Coptidis Rhizoma was more than 56 times. Conclusions: The usual usage of Coptidis Rhizoma during pregnancy seemed not to increase the adverse risk on foetal growth. Future observations for use of longer than 56 times or a higher cumulated dose were needed to clarify the safety.

AB - Purpose: To explore the effect or Coptidis Rhizoma on foetal growth in pregnancy. Methods: During 1985-1987, each pregnant woman with 26 or more weeks of gestation who came to the Taipei Municipal Maternal and Child Hospital for prenatal care was enrolled and interviewed by three trained interviewers using structured questionnaires to obtain detailed information including the herbal medicines used during pregnancy. Medical histories of diabetes, hypertension, antepartum haemorrhage and medicines used during pregnancy were abstracted from medical records of mothers'. Data of birth weight, gestational duration and characteristics of infants were gathered from the Taiwan national birth registration. A total of 9895 singleton livebirths were analysed. The variables related to foetal growth included two dichotomous measures: low birth weight (LBW) and small for gestational age (SGA); and one continuous measure: birth weight. Potential risk factors associated with these outcomes were investigated using multiple logistic and linear regression models. Results: After adjustment, pregnant women taking Coptidis Rhizoma during pregnancy had no significantly adverse effect on foetal growth. There was a non-significantly slightly decreased mean of birth weight and increased risk of LBW and SGA babies if the frequency of using Coptidis Rhizoma was more than 56 times. Conclusions: The usual usage of Coptidis Rhizoma during pregnancy seemed not to increase the adverse risk on foetal growth. Future observations for use of longer than 56 times or a higher cumulated dose were needed to clarify the safety.

UR - http://www.scopus.com/inward/record.url?scp=33645297125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645297125&partnerID=8YFLogxK

U2 - 10.1002/pds.1170

DO - 10.1002/pds.1170

M3 - Article

C2 - 16329158

AN - SCOPUS:33645297125

VL - 15

SP - 185

EP - 192

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 3

ER -